INTEMMA Trademark

Trademark Overview


On Wednesday, January 27, 2021, a trademark application was filed for INTEMMA with the United States Patent and Trademark Office. The USPTO has given the INTEMMA trademark a serial number of 90492348. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Tuesday, August 27, 2024. This trademark is owned by Teva Pharmaceuticals USA, Inc.. The INTEMMA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of ...
intemma

General Information


Serial Number90492348
Word MarkINTEMMA
Filing DateWednesday, January 27, 2021
Status733 - FOURTH EXTENSION - GRANTED
Status DateTuesday, August 27, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 21, 2021

Trademark Statements


Goods and ServicesPharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely, fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical preparations for the treatment of neurological disorders

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, April 29, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTeva Pharmaceuticals USA, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Party NameTeva Pharmaceuticals USA, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Trademark Events


Event DateEvent Description
Friday, August 13, 2021ASSIGNED TO EXAMINER
Saturday, August 14, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, January 30, 2021NEW APPLICATION ENTERED
Thursday, April 29, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, September 1, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, September 21, 2021PUBLISHED FOR OPPOSITION
Tuesday, September 21, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, November 10, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, November 10, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, November 10, 2021TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Wednesday, November 10, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, November 16, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, June 21, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Wednesday, June 22, 2022PETITION TO REVIVE-GRANTED
Wednesday, June 22, 2022TEAS PETITION TO REVIVE RECEIVED
Thursday, June 23, 2022NOTICE OF REVIVAL - E-MAILED
Friday, February 24, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, September 1, 2023SOU TEAS EXTENSION RECEIVED
Monday, May 16, 2022NOTICE OF ALLOWANCE CANCELLED
Friday, July 29, 2022NEW NOA TO ISSUE
Monday, June 20, 2022ABANDONMENT - NO USE STATEMENT FILED
Friday, July 29, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, September 6, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, February 22, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, February 22, 2023SOU EXTENSION 1 FILED
Wednesday, February 22, 2023SOU EXTENSION 1 GRANTED
Friday, September 1, 2023SOU EXTENSION 2 FILED
Friday, September 1, 2023SOU EXTENSION 2 GRANTED
Friday, March 1, 2024SOU EXTENSION 3 GRANTED
Tuesday, September 5, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, March 1, 2024SOU TEAS EXTENSION RECEIVED
Friday, March 1, 2024SOU EXTENSION 3 FILED
Saturday, March 2, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 27, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, August 27, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 27, 2024SOU EXTENSION 4 FILED
Tuesday, August 27, 2024SOU EXTENSION 4 GRANTED
Thursday, February 20, 2025SOU TEAS EXTENSION RECEIVED